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Abstract
Background:  It is well known that most neurodegenerative diseases are associated with
microglia-mediated inflammation. Our previous research demonstrates that the CD40 signaling is
critically involved in microglia-related immune responses in the brain. For example, it is well known
that the activation of the signal transducer and activator of transcription (STAT) signaling pathway
plays a central role in interferon-gamma (IFN-γ)-induced microglial CD40 expression. We and
others have previously reported that microglial CD40 expression is significantly induced by IFN-γ
and amyloid-β (Aβ) peptide. Recent studies have shown that certain flavonoids possess anti-
inflammatory and neuroprotective properties distinct from their well-known anti-oxidant effects.
In particular, flavonoids, apigenin and luteolin have been found to be effective CD40
immunomodulators.
Methods: Cultured microglia, both N9 and primary derived lines, were treated with flavonoids in
the presence of IFN-γ and/or CD40 ligation to assess any anti-inflammatory effects and/or
mechanisms. CD40 expression on microglia was analyzed by fluorescence activated cell sorting
(FACS). Anti-inflammatory effects and mechanisms were confirmed by ELISA for interlekin-6 (IL-
6) and TNF-α, lactate dehydrogenase (LDH) assay, and STAT1 Western blotting.
Results:  Apigenin and luteolin concentration-dependently suppressed IFN-γ-induced CD40
expression. Apigenin and luteolin also suppressed microglial TNF-α and IL-6 production stimulated
by IFN-gamma challenge in the presence of CD40 ligation. In addition, apigenin and luteolin
markedly inhibited IFN-γ-induced phosphorylation of STAT1 with little impact on cell survival.
Conclusion: Our findings provide further support for apigenin and luteolin's anti-inflammatory
effects and suggest that these flavonoids may have neuroprotective/disease-modifying properties in
various neurodegenerative disorders, including Alzheimer's disease (AD).
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Background
Multiple lines of evidence suggest microglia, the resident
immune cells of the central nervous system (CNS), play a
critical role in the etiology of various neurodegenerative
diseases. Chronic activation of microglia is believed to
trigger and maintain an inflammatory response, which
may ultimately lead to neuronal cell death such as that
observed in Alzheimer's disease (AD), HIV-dementia, Par-
kinson's disease, prion disease, amyotrophic lateral scle-
rosis, and multiple sclerosis [1-11]. In fact, this chronic
activation exposes the CNS to elevated levels of a wide
array of potentially neurotoxic molecules including pro-
inflammatory cytokines, complement proteins, protein-
ases, and reactive oxygen species (ROS) [12-17]. Con-
versely, an alternative view suggests that dysregulation of
microglial activation may prevent appropriate immune
responses necessary to respond to neuroinsults [18].
Essential to microglial activation is the stimulatory signal
from CD40 ligation. CD40 and its ligand (CD40L) are key
immunoregulatory molecules that provide co-stimulatory
input to cells from both the innate and adaptive arms of
the immune system [19-22]. The classical stimulatory sig-
nal for microglial activation is propagated by T-cell release
of interferon-gamma (IFN-γ), which consequently sensi-
tizes the microglia by upregulating the expression of vari-
ous immunoregulatory molecules, including CD40, on
their cell surfaces [23,24]. Furthermore, it is well known
that the activation of the Janus kinase/signal transducer
and activator of transcription (JAK/STAT) signaling path-
way plays a central role in this IFN-γ-induced microglial
CD40 expression [25,26]. We have previously reported
that microglial CD40 expression is significantly increased
by IFN-γ in the presence of β-amyloid (Aβ) peptide via
STAT1 activation [27,28]. Accordingly, modulation of the
JAK/STAT signaling pathway may not only prove to be an
effective means for suppressing microglial-mediated
inflammation but also an important target for neurode-
generative disease therapy.
While several anti-inflammatory drugs have been found
to prevent microglial-mediated inflammation, their
underlying mechanisms remain unclear and the search for
more effective practical compounds continues. Recent
research has focused on the analysis of flavonoids, which
epidemiological study suggest are beneficial against the
neurodegeneration and aging processes [29-33]. Flavo-
noids, a group of phenolic phytochemicals, are common
in vascular plants and are abundant in particular spices,
vegetables, and fruits. They are considered important con-
stituents in the human diet, although their daily intake
varies with dietary habits [34,35]. Several medicinal prop-
erties have been ascribed to flavonoids, notably anti-oxi-
dant [36,37], anti-carcinogenic [38,39], and anti-
inflammatory activity [40-42]. One such flavonoid, api-
genin, and its phase I metabolite, luteolin, have been
found to reduce CD40 and CD40L expression on den-
dritic cells and basophils, respectively [43,44]. Previous
research has also shown apigenin's ability to inhibit pro-
inflammatory cytokines production by monocytes, mac-
rophages, and microglia and further substantiates this
compound as versatile immunomodulator [45-49].
In the present study, we investigate the potential anti-
inflammatory effects and mechanisms of these flavo-
noids, apigenin and luteolin, in cultured microglia. Our
findings demonstrate that treatment of both N9 and
murine-derived primary microglia cell lines with apigenin
and luteolin significantly reduces CD40 expression
induced by IFN-γ. This reduction is paralleled by signifi-
cant decreases in the release of the pro-inflammatory
cytokines interleukin-6 (IL-6) and tumor necrosis factor-α
(TNF-α) by the microglia. Furthermore, data show that
apigenin and luteolin treatments achieve these reductions
through inactivation of STAT1 and suggest a mechanism
whereby these compounds may prove to be an effective
therapy for neurodegeneration.
Methods
Animals and microglial cell cultures
Breeding pairs of BALB/c mice were purchased from Jack-
son Laboratory (Bar Harbor, ME) and housed in the ani-
mal facility at the University of South Florida, College of
Medicine. Murine primary culture microglia were isolated
from mouse cerebral cortices and grown in RPMI 1640
medium supplemented with 5% FCS, 2 mM glutamine,
100 U/ml penicillin, 0.1 μg/ml streptomycin, and 0.05
mM 2-mercaptoethanol according to previously described
methods [50]. Briefly, cerebral cortices from newborn
mice (1–2 day-old) were isolated under sterile conditions
and were kept at 4°C before mechanical dissociation.
Cells were plated in 75 cm2 flasks and complete medium
was added. Primary cultures were kept for 14 days so that
only glial cells remained and microglial cells were isolated
by shaking flasks at 200 rpm in a Lab-Line incubator-
shaker. More than 98% of these glial cells stained positive
for microglial marker Mac-1 (CD11b/CD18; Boehringer
Mannheim, Indianapolis, IN; data not shown). All animal
protocols were approved by the Committee of Animal
Research at the University of South Florida, in accordance
with the National Institutes of Health guidelines. N9
microglial originally generated from myc-immortalized
mice were cultured as previously described [50,51].
Briefly, N9 microglial cells were maintained and plated in
75 cm2 flasks with MEM medium supplemented with 5%
FCS and 2 mM glutamine.
Flow cytometric analysis of microglial CD40 expression
Primary cultured microglial cells were plated in 6-well tis-
sue culture plates at 5 × 105 cells/well and incubated with
apigenin and luteolin at different doses in the presence orJournal of Neuroinflammation 2008, 5:41 http://www.jneuroinflammation.com/content/5/1/41
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absence of IFN-γ (100 U/ml). Eight hours after incuba-
tion, these microglial cells were washed with flow buffer
[PBS containing 0.1% (w/v) sodium azide and 2% (v/v)
FCS] and re-suspended in 250 μl of ice-cold flow buffer
for fluorescence activated cell sorting (FACS) analysis,
according to methods described previously [50]. Briefly,
cells were pre-incubated with anti-mouse CD16/CD32
monoclonal antibody (clone 2.4G2, PharMingen, Los
Angeles, CA) for 10 min at 4°C to block non-specific
binding to Fc receptors. Cells were then spun down at
5,000 g washed 3 times with flow buffer and then incu-
bated with hamster anti-mouse CD40-FITC or isotype
control antibody-FITC (1:100 dilution; PharMingen) in
flow buffer. After 30 min incubation at room temperature,
cells were washed twice with flow buffer, re-suspended in
250 μL of flow buffer and analyzed by a FACScan™ instru-
ment (Becton Dickinson, Franklin Lanes, NJ). A mini-
mum of 10,000 cells were accepted for FACS analysis.
Cells were gated based on morphological characteristics
such that apoptotic and necrotic cells were not accepted
for FACS analysis using CellQuest™ software (Beckton
Dickinson). Percentages of positive cells (i.e. CD40-
expressing) were calculated as follows: for each treatment,
the mean fluorescence value for the isotype-matched con-
trol antibody was subtracted from the mean fluorescence
value for the CD40-specific antibody.
TNF-α, IL-6, and LDH analyses
Murine primary cultured microglial cells were plated in
24-well tissue-culture plates (Costar, Cambridge, MA) at 1
× 105 cells per well and stimulated for 12 hr with either
IFN-γ (100 U/ml)/CD40 agonistic antibody (2 μg/ml)
(R&D Systems, Minneapolis, MN) in the presence or
absence of apigenin and luteolin at a range of concentra-
tions. Cell-free supernatants were collected and stored at -
70°C until analysis. TNF-α and IL-6 levels in the superna-
tants were examined using ELISA kits (R&D Systems) in
strict accordance with the manufacturers' protocols. Cell
lysates were also prepared and the BCA protein assay
(Pierce Biotechnology, Rockford, IL) was performed to
measure total cellular protein. Results are shown as mean
pg of TNF-α or IL-6 per mg of total cellular protein (+/-
SD). Cell death was measured from lactate dehydrogenase
(LDH) release in the cell-free supernatants using a Cyto-
Tox 96® Non-Radioactive Cytotoxicity Assay kit (Promega,
Madison, WI).
STAT1 signaling pathway analysis
Primary culture microglial cells were plated in 6-well tis-
sue culture plates at a density of 5 × 105 cells per well and
co-incubated with IFN-γ (100 U/mL) in the presence or
absence of a dose range of apigenin or luteolin for 30 min.
At the end of the treatment period, microglial cells were
washed in ice-cold PBS three times and lysed in ice-cold
lysis buffer. After incubation for 30 min on ice, samples
were centrifuged at high speed for 15 min, and superna-
tants were collected. Total protein content was estimated
using the BCA protein assay (Pierce Biotechnology). Aliq-
uots corresponding to 100 μg of total protein was electro-
phoretically separated using 10% Tris gels.
Electrophoresed proteins were then transferred to PVDF
membranes (Bio-Rad, Richmond, CA), washed in dH2O,
and blocked for 1 hour at ambient temperature in TBS
containing 5% (w/v) non-fat dry milk. After blocking,
membranes were hybridized for 1 h at ambient tempera-
ture with various primary antibodies. Membranes were
then washed 3 × for 5 min each in dH2O and incubated
for 1 hour at ambient temperature with the appropriate
HRP-conjugated secondary antibody (1:1,000, Pierce Bio-
technology). All antibodies were diluted in TBS contain-
ing 5% (w/v) of non-fat dry milk. Blots were developed
using the luminol reagent (Pierce Biotechnology). Densi-
tometric analysis was conducted using a FluorS Multiim-
ager with Quantity One™ software (BioRad, Hercules,
CA). For STAT1 phosphorylation, membranes were
probed with a phospho-Ser727 STAT1 antibody or a
phospho-Tyr701 STAT1 antibody (Cell Signaling Tech-
nology, Danvers, MA) and stripped with stripping solu-
tion and then re-probed with antibody that recognize
total STAT1 (Cell Signaling Technology).
Statistical analysis
All data were normally distributed; therefore, in instances
of single mean comparisons, Levene's test for equality of
variances followed by t-test for independent samples was
used to assess significance. In instances of multiple mean
comparisons, analysis of variance (ANOVA) was used, fol-
lowed by post-hoc  comparison using Bonferonni's
method. Alpha levels were set at 0.05 for all analyses. The
statistical package for the social sciences release 10.0.5
(SPSS Inc., Chicago, IL, USA) was used for all data analy-
sis.
Results
Apigenin and luteolin suppress IFN-γ-induced CD40 
expression in N9 and murine-derived primary microglial 
cells
To examine the effect apigenin and luteolin had on micro-
glial activation via CD40, we initially treated N9 microglia
cells over a range of concentrations. Following FACS anal-
ysis, we found that both compounds significantly reduced
CD40 expression on the microglial cell surface (p < 0.01,
Fig. 1). As illustrated in Figure 1, we clearly observe a con-
centration-dependent decrease in CD40 expressing cells
starting at 3.125 μM through 50 μM. As these compounds
have been reported to be potentially cytotoxic, we also
examined the level of microglial cell death in response to
apigenin and luteolin treatment by LDH assay [52]. We
discovered that apigenin and luteolin treatment only
induced significant cell death at a 50 μM concentration inJournal of Neuroinflammation 2008, 5:41 http://www.jneuroinflammation.com/content/5/1/41
Page 4 of 10
(page number not for citation purposes)
either N9 or primary microglial cells, which along with
the data from Figure 1 suggested that 25 μM may be the
most efficacious concentration for regulating CD40
expression (Fig. 2C and 2D). Further, to determine if this
reduction in CD40 expression continues through micro-
glial activation, we treated both N9 and primary microglia
cells with 25 μM of apigenin or luteolin in the presence of
a stimulatory amount of IFN-γ as shown in figure 2. Fol-
lowing FACS analysis, we once more found that both
compounds significantly reduced CD40 expressing cells
as compared to positive control in both cell lines (p <
0.01, Fig. 2A and 2B). Taken together, the above data sug-
gests that apigenin and luteolin may be able to modulate
microglial activation via CD40.
Apigenin and luteolin oppose the effects of IFN-γ/CD40 
ligation on TNF-α and IL-6 production in N9 and murine-
derived primary microglial cells
To confirm the functional inhibition of CD40 in micro-
glia, we treated both N9 and primary microglial cells with
25 μM of either apigenin or luteolin in the presence of
IFN-γ and CD40 agonistic antibody. Following ELISA, we
observed reductions in both secreted levels of TNF-α and
IL-6 from flavonoid treated microglia as compared to pos-
itive control (Fig. 3). As shown in Figure 3, microglia co-
treated with a stimulatory concentration of IFN-γ and
CD40 agonistic antibody simulates activation, thereby
markedly elevating secretion of the archetypical pro-
inflammatory cytokines TNF-α and IL-6 and over negative
control. However, in the presence of apigenin or luteolin
TNF-α (Fig. 3A and 3B) and IL-6 (Fig. 3C and 3D) secre-
tion is significantly reduced (p < 0.01). Therefore, when
considering the above data, it is apparent that both api-
genin and luteolin modulate microglial activation and
may prevent microglial-mediated inflammation by sup-
pression of CD40 signaling.
Apigenin and luteolin inhibit IFN-γ-induced STAT1 
phosphorylation in N9 and murine-derived primary 
microglial cells
To establish the mechanism whereby apigenin and luteo-
lin decrease CD40 expression on the microglial cell sur-
face, we investigated the upstream STAT1 signaling
pathway. Both N9 and primary microglial cells were again
treated with a 25 μM concentration of either apigenin or
luteolin in the presence of a stimulatory amount of IFN-γ.
Following western blot analysis of cell lysates, we found a
decrease in STAT1 signaling in both flavonoid treatments
as compared to positive control (Fig. 4 and 5). Densito-
metric analyis of western blot data from N9 cell lysates in
Figure 4B indicate significant reductions in STAT1 phos-
phorylation at serine residue 727 (p < 0.01) with both api-
genin and luteolin treatment. However, densitometric
analysis of western blot data from primary microglial cells
in Figure 5B and 5C reveals that apigenin significantly
reduces STAT1 phosphorylation at tyrosine residue 701 (p
< 0.01) and luteolin significantly reduces STAT1 phospho-
rylation at serine residue 727 (p < 0.01). Importantly, api-
genin and luteolin treatment does not appear to affect
holoprotein levels of STAT1 (Fig. 4A and 5A). Interest-
ingly, we observed slight increases in STAT1 phosphoryla-
tion at serine 727 with flavonoid treatment alone, which
may suggest these compounds have other unrelated, sep-
arate mechanisms. All in all, the above data suggest that
apigenin and luteolin treatment regulates STAT1 at the
level of phosphorylation and prevents the necessary sign-
aling, in response to IFN-γ, required to induce CD40
expression.
Discussion
Compounds that modulate microglial activity would be
indispensable tools in neurodegenerative disease therapy.
Here, we identify two flavonoids, apigenin and luteolin,
that reduce CD40 expression on microglia and elucidate a
mechanism whereby these compounds may prevent
harmful neuroinflammation. The transcription factor
STAT1 has been a potential therapeutic target in our pre-
vious neurodegeneration research. It is becoming evident
that STAT1 and related signaling proteins may be regu-
lated by flavonoids. Apigenin and luteolin appear to affect
Apigenin and luteolin reduce microglial CD40 expression  induced by IFN-γ in a concentration dependent manner Figure 1
Apigenin and luteolin reduce microglial CD40 
expression induced by IFN-γ in a concentration 
dependent manner. FACS analysis showed significant con-
centration dependent decreases in IFN-γ-induced CD40 
expression by both apigenin and luteolin following 8 hrs. of 
co-treatment in N9 cells seeded in 6-well tissue-culture 
plates (5 × 105/well). Data were represented as mean % of 
CD40 expressing cells (+/- SD). Results are representative of 
three independent experiments.
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the phosphorylation status of tyrosine 701 and serine
727, which is required for STAT dimerization and maxi-
mal activation of transcription, respectively [53,54]. Even
though we do observe slight increases in serine 727 STAT1
phosphorylation with flavonoid treatment alone (Fig. 4
and 5), it is likely that this phenomenon is related to these
compounds' pro-apoptotic effects evidenced in tumor cell
lines [55,56]. In a study by Elsisi and colleagues, apigenin
was found to induce apoptosis in the BV-2 microglial cell
line after 24 hours of incubation [57]. However, in our
present study it is apparent that a 25 μM concentration of
apigenin may be at worst cytostatic towards both the pri-
mary derived and the "transformed/immortalized" N9
microglia with treatment times under 24 hours (Fig. 2C
and 2D). It has been reported that regulation of apoptosis
via STAT1 is dependent upon serine 727 phosphorylation
[58-60]. In contrast, we observe significant reductions in
serine 727 phosphorylation with apigenin in N9 micro-
Apigenin and luteolin inhibit microglial CD40 expression induced by IFN-γ Figure 2
Apigenin and luteolin inhibit microglial CD40 expression induced by IFN-γ. N9 and murine-derived primary micro-
glial cells were seeded in 6-well tissue-culture plates (5 × 105/well) for FACS analysis and 24-well tissue-culture plates (1 × 105/
well) for LDH analysis in parallel. Cultured cells were co-treated with IFN-γ (100 U/mL) in the presence or absence of apigenin 
and luteolin (25 μM) or treated with vehicle (1% DMSO; control) for 8 hrs. For A and B, FACS analysis showed significant 
decreases by both apigenin and luteolin (25 μM) in IFN-γ-induced CD40 expression in N9 cells and primary microglia. Data are 
represented as mean % of CD40 expressing cells (+/- SD). For C and D, cultured supernatants were collected and subjected to 
LDH assay as indicated. Data showed no significant increase in cell toxicity below a 50 μM concentration of either flavonoid in 
both N9 or primary microglial cells. Data were represented as mean % of total cell death as determined by LDH present dur-
ing complete lysis (+/- SD). For A, B, C and D. Results are representative of three independent experiments. (*p < 0.05; **p < 
0.01).
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glia and luteolin in both N9 and primary microglia in the
presence of IFN-γ (Fig. 4 and 5). Therefore, it may be likely
that the pro-apoptotic/anti-carcinogenic and immu-
nomodulatory mechanisms of these flavonoids interface
at the level of STAT1, a molecule qualified to function in
this capacity. Still, distinct differences between these
mechanisms may be dependent on the microenviron-
ment and remain to be established.
While phosphorylation of tyrosine residue 701 on STAT1
is an event essential for STAT dimerizaton and transloca-
tion, it neither is a required precursor to serine 727 phos-
phorylation nor a mediator of apoptosis [58-60].
However, it appears to be as necessary as serine 727 phos-
phorylation for STAT1 signaling as apigenin effectively
reduces CD40 expression in the presence of IFN-γ in pri-
mary microglia (Fig. 2B). Interestingly, we find that api-
genin appears to regulate tyrosine 701 phosphorylation,
but not serine 727 phosphorylation, of STAT1 in primary
microglia, which suggests that it has a distinct target/
mechanism separate from that of luteolin. Furthermore,
these mechanistic differences underscore the differences
inherent between primary derived and N9 microglia.
The ability of these flavonoids to regulate CD40-CD40L
interaction and consequently pro-inflammatory media-
tors may be useful in the treatment of many inflammatory
diseases. Nonetheless, inflammation in neurodegenera-
Apigenin and luteolin oppose the effects of IFN-γ/CD40 ligation on TNF-α and IL-6 production in microglial cells Figure 3
Apigenin and luteolin oppose the effects of IFN-γ/CD40 ligation on TNF-α and IL-6 production in microglial 
cells. N9 and murine-derived primary microglial cells were seeded in 24-well tissue-culture plates (1 × 105/well) and co-
treated with IFN-γ (100 U/mL)/agonistic anti-CD40 antibody (CD40 Ab; 2 μg/mL) in the presence or absence of apigenin and 
luteolin (25 μM) or treated with vehicle (1% DMSO; control) for 12 hrs. Cell cultured supernatants were collected and sub-
jected to cytokine ELISA as indicated. Data were represented as mean pg of each cytokine in mg of total cellular protein (+/- 
SD). Results are representative of three independent experiments. (**p < 0.01).
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tive disease represents a specific immunoprofile, involv-
ing discrete units made up of glial cells and neurons.
Complete abolishment of CD40-CD40L interactions
between microglia, astrocytes, and neurons may prove to
be hazardous, as we have previously shown that ligation
of CD40 protected neuronal cells from nerve growth fac-
tor-β (NGF-β) or serum withdrawal-induced injury and
promoted differentiation [61]. Rather, modulation of
immune reactions in CNS would appear to be the most
appropriate course of action for treating neurodegenera-
tive disease. While it would be quite difficult to achieve
this modulation with conventional drugs, flavonoids
appear to be uniquely fitted to this task as we observe their
ability to affect multiple converging signaling pathways.
For instance, apigenin and luteolin appear to regulate ser-
ine 727 phosphorylation of STAT1 at levels that are poten-
tially conducive to apoptosis, all the while keeping a
damper on levels in the presence of IFN-γ (Fig. 4 and 5).
It is in this way that these compounds are essentially pro-
moters of homeostasis.
It is quite clear from both the present study and previous
research that apigenin and luteolin are potentially safe
and effective immunomodulators, although their direct
molecular targets have not been identified. What seems to
be apparent is that these compounds prevent STAT1 sign-
aling, which consequently may prevent the transcription
of its target genes. Even as these compounds affect STAT1,
it is more likely that upstream kinases or phosphatases are
directly involved. Phosphatidylinositol 3-kinase (PI3K),
its effector kinase Akt, JAK1, and JAK2 are all required for
phosphorylation of both serine 727 and tyrosine 701 of
STAT1 [62]. Accordingly, these kinases are all potential
molecular targets of apigenin and luteolin. Previous
reports also suggest that similar flavonoids mediate their
effects through protein tyrosine phosphatases. Further-
more, CD45, a protein tyrosine phosphatase important
for immune regulation and function, has been identified
as an upstream regulator of STAT1 signaling via dephos-
phorylation of JAKs [63]. In light of these findings, it may
be important to evaluate the effects of these flavonoids on
other potential immunoregulatory signaling molecules to
better ascertain both safety and efficacy.
While a major limitation in the use of these flavonoids as
immunomodulators or anti-inflammatory agents is their
low bioavailability, apigenin, in particular, may hold
some promise as a suitable therapeutic agent. Recent pK
studies suggest that apigenin exhibits a slow metabolism,
absorption, and elimination phase (92 hours in rats) [64-
66]. Moreover, in one human pK study, apigenin was also
found to significantly reduce measures of oxidative stress
in blood [67]. Like many aglycone forms of flavonoids,
apigenin and luteolin potentially reach their molecular
targets by passive diffusion through cell membranes. This
means of cellular uptake may explain the onset (<30
Apigenin and luteolin oppose IFN-γ-induced phosphorylation of STAT1 in N9 microglial cells Figure 4
Apigenin and luteolin oppose IFN-γ-induced phosphorylation of STAT1 in N9 microglial cells. N9 murine micro-
glial cells were seeded in 24-well tissue-culture plates (1 × 105/well) and treated with IFN-γ (100 U/mL) in the presence or 
absence of apigenin and luteolin (25 μM) or treated with vehicle (1% DMSO; control) for 30 mins. Cell lysates were prepared 
from these cells and subjected to western immunoblotting using anti-phospho-STAT1 (Ser727) and anti-total STAT1 antibody 
as indicated. For B, data are represented as mean ratios of phospho-Stat1(Ser727) to total Stat1 (+/- SD) from densitometric 
analyses. Results are representative of three independent experiments. (**p < 0.01).
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mins) of STAT1 inactivation as we observed following api-
genin and luteolin treatment (Fig. 3). Despite the possibil-
ity of sustainable therapeutic concentrations, future work
with these compounds will certainly need to address
blood-brain-barrier permeability.
Conclusion
In summary, flavonoids apigenin and luteolin may pre-
vent microglial-mediated inflammation by modulating
the induction of CD40 in response IFN-γ. This decrease in
expression modulates CD40-40L interactions, which are
critical to microglial activation. Apigenin and luteolin's
mechanism of action appears to be targeted at regulating
STAT1 activation. These studies may lay the foundation
for the development of neurodegenerative disease modi-
fying therapies focused on preventing harmful inflamma-
tion while maintaining proper glia-neuron interactions.
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Apigenin and luteolin oppose IFN-γ-induced phosphorylation of STAT1 in murine-derived primary microglial cells Figure 5
Apigenin and luteolin oppose IFN-γ-induced phosphorylation of STAT1 in murine-derived primary microglial 
cells. Murine-derived primary microglial cells were seeded in 24-well tissue-culture plates (1 × 105/well) and treated with IFN-
γ (100 U/mL) in the presence or absence of apigenin and luteolin (25 μM) or treated with vehicle (1% DMSO; control) for 30 
mins. Cell lysates were prepared from these cells and subjected to western immunoblotting using anti-phospho-STAT1 
(Ser727 or Tyr701) and anti-total STAT1 antibody as indicated. For B and C, data are represented as mean ratios of phospho-
Stat1(Ser727 or Tyr701) to total Stat1 (+/- SD) from densitometric analyses. Results are representative of three independent 
experiments. (**p < 0.01).
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